Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Sanofi-Aventis S.A. ADR (NQ: SNY ) 55.11 -0.11 (-0.20%) Streaming Delayed Price Updated: 10:02 AM EDT, Aug 22, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Sanofi-Aventis S.A. ADR < Previous 1 2 3 4 5 6 7 8 9 ... 27 28 Next > Move Over Magnificent 7, Say Hello to the GRANOLAS February 22, 2024 Dive into the compelling world of GRANOLAS stocks: Europe's elite players shaping the future of pharmaceuticals, tech, and consumer goods. Via InvestorPlace Rapt Therapeutics Crashes 65% After Unexpected Liver Failure Sidelines Two Tests February 20, 2024 The FDA put studies in eczema and asthma treatment on clinical hold. Via Investor's Business Daily Exposures Product Safety Cruising For A Bruising February 18, 2024 We’re currently living in the soft landing, and it is pleasant indeed. But inflation numbers at the start of the year have put us on notice. Like the Magnificent Seven, hopes of a sustained soft... Via Talk Markets Topics Economy Exposures Economy Interest Rates 2 Healthcare Stocks You Can Buy and Hold for the Next Decade February 16, 2024 Don't count these companies out too soon. Via The Motley Fool 7 Contrarian Biotech Stocks to Consider Amid Sector Weakness February 15, 2024 Although the healthcare innovation space has struggled recently, these contrarian biotech stocks now offer compelling discounts. Via InvestorPlace Why the dividend investor may take a look at NASDAQ:SNY. February 14, 2024 Exploring SANOFI-ADR (NASDAQ:SNY)'s dividend characteristics. Via Chartmill NASDAQ:SNY is an undervalued gem with solid fundamentals. February 14, 2024 SANOFI-ADR (NASDAQ:SNY) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals. Via Chartmill Sanofi's Earnings Outlook January 31, 2024 Via Benzinga The 3 Biotech Stocks That Could Make Your February Unforgettable February 15, 2024 After a blistering hot year of biotech M&A, we’ll see more of the same in 2024. That could be great news for these hot biotech stocks. Via InvestorPlace What's Going On Eli Lilly Stock Thursday? February 08, 2024 Eli Lilly's impressive stock surge, better-than-expected Q4 results, and positive analyst reviews. Via Benzinga Novo Nordisk To Up Production Capacity As Parent Buys Catalent February 05, 2024 NVO stock rose after Novo Nordisk's parent, Novo Holdings, said it has agreed to buy contract manufacturer Catalent for $11.5 billion in cash. Via Investor's Business Daily CytoReason's AI-Driven Disease Model Platform Trusted By 5 Top 10 Pharma Companies Harnesses Big Data To Speed Drug Discovery And Development February 05, 2024 Click here to learn more about CytoReason and how to invest through OurCrowd. Via Benzinga Week In Review: Shanghai Inmagene Signs $230 Million Deal To Develop Two HutchMed Immunology Assets February 03, 2024 Inmagene Biopharma of Shanghai transferred 7.5% of its shares to HutchMed for global rights to two clinical stage immunology assets. It will also be responsible for up to $230 million in milestones. Via Talk Markets Analyzing NASDAQ:SNY's Dividend Potential. January 24, 2024 Balancing Dividends and Fundamentals: The Case of SANOFI-ADR (NASDAQ:SNY). Via Chartmill Why Is Sanofi Partner Regeneron Pharmaceuticals Stock Trading Higher Today? February 02, 2024 Regeneron Pharmaceuticals Inc (NASDAQ:REGN) reported fourth-quarter adjusted EPS of $11.86, down 6% Y/Y, beating the consensus of $10.77. Via Benzinga Sanofi (SNY) Q4 2023 Earnings Call Transcript February 01, 2024 SNY earnings call for the period ending December 31, 2023. Via The Motley Fool Topics Earnings Exposures Financial Why C.H. Robinson Shares Are Trading Lower By Over 12%? Here Are Other Stocks Moving In Thursday's Mid-Day Session February 01, 2024 Shares of C.H. Robinson Worldwide, Inc. (NASDAQ: CHRW) fell sharply during Thursday’s session after the company reported worse-than-expected fourth-quarter financial results. Via Benzinga French Pharma Giant Sanofi's Q4 Earnings Hit By Aubagio Generic Competition, Helped By Flagship Eczema And Newly Launched Hemophilia Drugs February 01, 2024 Sanofi reports Q4 operating income of €2.6B, down 5.2%. Revenues rise 1.8% to €10.92B, Specialty Care grows 13.7%, Dupixent sales surge. Via Benzinga Sanofi's Biggest Drug Shined. But The Rest Of Its Business Didn't. February 01, 2024 The company missed total sales and earnings expectations. Via Investor's Business Daily Nasdaq Futures Rebound As Traders Eye Apple, Meta, Amazon Earnings: Analyst Flags 'January Barometer' That Bodes Well For The Year February 01, 2024 After ending January with modest gains, the major averages now look to earnings catalysts to drive momentum, with futures higher in first trading session of February. Via Benzinga MaxLinear Reports Q4 Results, Joins ING, Wolfspeed And Other Big Stocks Moving Lower In Thursday's Pre-Market Session February 01, 2024 U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 90 points on Thursday. Via Benzinga Earnings Scheduled For February 1, 2024 February 01, 2024 Companies Reporting Before The Bell • ING Groep (NYSE:ING) is expected to report earnings for its fourth quarter. • Shell (NYSE:SHEL) is likely to report quarterly earnings at $1.81 per share on... Via Benzinga Tech Titans Microsoft, Apple Lead 'Magnificent Seven' Earnings Wave This Week: Can Mega-Caps Ignite Market Optimism? January 29, 2024 An analyst sees the Satya Nadella-led company's earnings to be the key barometer for AI spending. Via Benzinga Topics Artificial Intelligence Exposures Artificial Intelligence Regeneron/Sanofi's Largest Selling Drug Dupixent Scores FDA Approval For Infants With Esophagus Inflammation January 26, 2024 FDA approves Dupixent (dupilumab) by Regeneron/Sanofi for pediatric eosinophilic esophagitis treatment. Breakthrough treatment for young patients. Via Benzinga Exposures Product Safety Sanofi Barrels Into Liver Disease Space With $1.7 Billion Takeover Of Inhibrx January 23, 2024 The company is buying Inhibrx, which is working on a treatment for alpha-1 antitrypsin deficiency. Via Investor's Business Daily French Drugmaker Sanofi Agrees To Buy Inhibrx's Candidate For Rare Genetic Indication, For About $2.2B January 23, 2024 Sanofi's strategic acquisition of Inhibrx's INBRX-101, a alpha-1 antitrypsin therapy in a registrational trial. Learn about the $2.2B merger details and Inhibrx Biosciences' spin-off. Closing expected... Via Benzinga Olympic Sponsor Sanofi Makes Major Play In Rare Disease Arena $2.2 Billion Acquisition Of Inhibrx Project January 23, 2024 Following the acquisition, New Inhibrx will continue to operate under the "Inhibrx" name, with Mark Lappe as Chairman and CEO. Via Benzinga Aclaris Therapeutics' ATI-1777 Faces Uphill Battle In Atopic Dermatitis Treatment Landscape, Analyst Downgrades January 22, 2024 HC Wainwright downgrades Aclaris Therapeutics post Phase 2b results of ATI-1777 for atopic dermatitis. Analyzing efficacy, commercial prospects, and competitive landscape. Via Benzinga Why Big Pharma Led By Merck, Sanofi, Teva Are Pouring Billions Into A New Immunology Space January 12, 2024 The companies are working on blocking TL1A, a protein tied to inflammatory bowel disease. Via Investor's Business Daily Sanofi's Olympic Endeavor: Leap Into Olympic Sponsorship Signals Cultural Transformation January 10, 2024 French pharmaceutical giant Sanofi SA (NASDAQ: SNY) is making an unconventional stride by sponsoring the 2024 Olympic Games in Paris in an effort to rejuvenate the company's image, attract a younger... Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 ... 27 28 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.